Pain mechanisms and pathways

Current Anaesthesia and Critical Care

Volumn 10, Issue 2, 1999, Pages 98-104

  Rice, A S C ^a   Justins, D M ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; ANALGESIC AGENT; EXCITATORY AMINO ACID; GLUTAMIC ACID; GLYCINE; NEUROTRANSMITTER; OPIATE; SOMATOSTATIN; TAURINE;

BRAIN CORTEX; CHRONIC PAIN; HUMAN; INFLAMMATION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE INJURY; NEUROTRANSMISSION; NOCICEPTION; NOCICEPTIVE RECEPTOR; PAIN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VISCERAL PAIN;

EID: 0032809722     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-7112(99)90008-X     Document Type: Article

References (28)

1. Meyer R A. Campbell J N. Raja S N. Peripheral neural mechanisms of nociception. In: Wall P D, Melzack R, eds. Textbook of Pain. Edinburgh: Churchill Livingstone, 1994; 13-44.
2. McMahon S B, Dmitrieva N, Koltzenburg M. Visceral pain. Br J Anaesth 1995; 75: 132-144.
3. Dickenson A H. Spinal cord pharmacology of pain. Br J Anaesth 1995; 75: 193-200.
4. Wall P D, Melzack R. Pain mechanisms: a new theory. Science 1965; 150: 971-979.
5. Scott H C F, Jaggar S I, Rice A S C. Mechanical hyperalgesia is referred to the hind limb following inflammation of the urinary bladder in the rat. J Physiol Lond 1998; 507: 18.
6. Coderre T J, Katz J, Vaccarino A. Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259-285.
7. Willis W D, Coggeshall R E. Sensory mechanisms of the spinal cord. In: Sensory mechanisms of the Spinal Cord. New York: Plenum Press, 1991.
8. Hirshberg R M, Al-Chaer E D, Lawand N B, Westlund K N, Willis W D. Is there a pathway in the posterior funiculus that signals visceral pain? Pain 1996; 67: 291-305.
9. Torebjörk H, Lundberg L E R, LaMotte R H. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol Lond 1992; 448: 765-780.
10. McMahon S B, Koltzenburg M. Silent afferents and visceral pain. In: Fields M L, Liebeskind J C, eds. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Seattle: IASP Press. 1994; 11-30.
11. Dray A. Inflammatory mediators of pain. Br J Anaesth 1995; 75: 125-131.
12. Dmitrieva N, Shelton D, Rice A S C, McMahon S B. The role of nerve growth factor in a model of visceral inflammation. Neuroscience 1997; 78: 449-459.
13. McMahon S B, Bennett D L H. Growth factors and pain. In: Dickenson A H. Besson J. eds. The Pharmacology of pain. Berlin: Springer, 1997; 135-157.
14. Levi-Montalcini R, Skaper S D, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Ncurosci 1996; 19: 514-520.
15. Pertwee R G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180.
16. Jaggar S I, Hasnie F S, Sellaturay S, Rice A S C. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide investigated in models of visceral and somatic inflammatory pain. Pain 1998; 76: 189-199.
17. Richardson J D, Kilo S, Hargreaves K M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral C B 1 receptors. Pain 1998; 75: 111-119.
18. Stein C, Schafer M, Cabot P J et al. Peripheral opioid analgesia. Pain Rev 1997; 4: 173-187.
19. Sawynok J, Reid A, Poon A. Peripheral antinociceptive effect of an adenosine kinase inhibitor, with augmentation by an adenosine deaminase inhibitor, in the rat formalin test. Pain 1998; 74: 75-81.
20. Woolf C J. Windup and central sensitization are not equivalent. Pain 1996; 66: 105-108.
21. Rice A S C. Topical spinal administration of a nitric oxide synthase inhibitor prevents the hyper-reflexia associated with a rat model of persistent visceral pain. Neurosci Lett 1995; 187: 1-4.
22. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing [published erratum appears in Pain 1995; 60(3): 353]. Pain 1994; 59: 9-43.
23. Meller S T, Gebhart G F. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 1993; 52: 127-136.
24. Rice A S C, Lloyd J, Bullingham R E, O'Sullivan G M. Ketorolac penetration into the cerebrospinal fluid of humans. J Clin Anaesth 1993; 5: 459-462.
25. Bennett D L H, French J, Priestley J V, McMahon S B. NGF hut not NT-3 or BDNF prevents the A fiber sprouting into lamina II of the spinal cord that occurs following axolomy. Mol Cell Neurosci 1996; 8: 211-220.
26. Thompson S W N, Majithia A A. Leukemia inhibitory factor induces sympathetic sprouting in intact dorsal root ganglia in the adult rat in vivo. J Physiol Lond 1998; 506: 809-816.
27. Stanfa L C, Dickenson A H, Xu X J, Wiesenfeld Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 1994; 15: 65-66.
28. Stamford J A. Descending control of pain. Br J Anaesth 1995; 75: 217-227.